Low cholesterol syndrome and drug development.
Handhle A, Viljoen A, Ramachandran R, Wierzbicki AS.
Curr Opin Cardiol. 2020 Jul;35(4):423-427. doi: 10.1097/HCO.0000000000000745.
Lipoproteins and cholesterol homeostasis in paediatric nephrotic syndrome patients.
Simachew YM, Antonić T, Gojković T, Vladimirov S, Mihajlović M, Vujčić S, Miloševski-Lomić G, Vekić J, Zeljković A, Spasojević-Kalimanovska V, Peco-Antić A, Paripović D, Stefanović A.
Biochem Med (Zagreb). 2022 Jun 15;32(2):020706. doi: 10.11613/BM.2022.020706.
Cholesterol microembolization syndrome.
Kay JM.
CMAJ. 2010 Oct 19;182(15):1647; author reply 1647. doi: 10.1503/cmaj.110-2114.
The role of long noncoding RNA in lipid, cholesterol, and glucose metabolism and treatment of obesity syndrome.
Lu Q, Guo P, Liu A, Ares I, Martínez-Larrañaga MR, Wang X, Anadón A, Martínez MA.
Med Res Rev. 2021 May;41(3):1751-1774. doi: 10.1002/med.21775. Epub 2020 Dec 24.
The Smith-Lemli-Opitz syndrome.
Kelley RI, Hennekam RC.
J Med Genet. 2000 May;37(5):321-35. doi: 10.1136/jmg.37.5.321.
Coronavirus Infection and Cholesterol Metabolism.
Dai J, Wang H, Liao Y, Tan L, Sun Y, Song C, Liu W, Qiu X, Ding C.
Front Immunol. 2022 Apr 21;13:791267. doi: 10.3389/fimmu.2022.791267. eCollection 2022.
Association of Cholesterol and Oxysterols in Adipose Tissue With Obesity and Metabolic Syndrome Traits.
Baila-Rueda L, Cenarro A, Lamiquiz-Moneo I, Marco-Benedi V, Gracia-Rubio I, Casamayor-Franco MC, Arbones-Mainar JM, Civeira F, Laclaustra M.
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3929-e3936. doi: 10.1210/clinem/dgac188.
Association of lipid rafts cholesterol with clinical profile in fragile X syndrome.
Toupin A, Benachenhou S, Abolghasemi A, Laroui A, Galarneau L, Fülöp T, Corbin F, Çaku A.
Sci Rep. 2022 Feb 21;12(1):2936. doi: 10.1038/s41598-022-07064-z.
Remnant cholesterol can identify individuals at higher risk of metabolic syndrome in the general population.
Zou Y, Kuang M, Zhong Y, Jiang C.
Sci Rep. 2023 Apr 12;13(1):5957. doi: 10.1038/s41598-023-33276-y.
Patterns of cholesterol metabolism: pathophysiological and therapeutic implications for dyslipidemias and the metabolic syndrome.
Lupattelli G, De Vuono S, Mannarino E.
Nutr Metab Cardiovasc Dis. 2011 Sep;21(9):620-7. doi: 10.1016/j.numecd.2011.04.010. Epub 2011 Aug 19.
